Acrivon Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $60.0M | $64.0M | $46.0M | $23.9M | — |
| Operating expenses | $84.1M | $89.2M | $67.1M | $32.7M | $16.2M |
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M |
| Pretax income | -$77.8M | -$80.4M | — | — | — |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M | -$16.2M |
| Balance Sheet | |||||
| Cash and equivalents | $41.5M | $39.8M | $36.0M | $29.5M | $99.6M |
| Current assets | $120.4M | $181.6M | $129.7M | $132.1M | $100.4M |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M |
| Current liabilities | $15.7M | $17.2M | $13.3M | $6.5M | $2.9M |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M |
| Stockholders' equity | $112.5M | $176.8M | $121.2M | $170.5M | -$23.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M |
| Depreciation and amortization | $1.4M | $1.0M | $536,000 | $364,000 | $37,000 |
| Stock-based compensation | $14.7M | $14.3M | $11.6M | $2.2M | $497,000 |
| Capital expenditure | $1.7M | $2.8M | $1.3M | $2.2M | $238,000 |
| Free cash flow | -$65.3M | -$68.4M | -$43.9M | -$32.3M | -$14.2M |
Shares outstanding 42.8M · Free float 52.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.